Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

Abstract

EGFR, KRAS, and TP53 gene mutations were not independently associated with the prognosis for Japanese patients with surgically treated lung adenocarcinoma.

Bioinformatics Analysis Reveals Connection of Squamous Cell Carcinoma and Adenocarcinoma of the Lung

“…Of these TFs, TP53 and PGR have high expression in the two subtypes while SP3, SMAD4 and ESR2 have low expression, which suggesting that these TFs may play an important role both in AC and SCC. These expression profiles also found in previous studies (Takahashi et al, 1989;Bodner et al, 1992;Kosaka et al, 2009) of lung cancer.…”

Comment on prognostic value of epidermal growth factor receptor mutation subtypes in surgically resected non-small cell lung cancer

“…This study was restricted to patients who had no adjuvant or neoadjuvant systemic therapy administered and focused solely on the postoperative prognostic differences among different genotypes. On the other hand, Kosaka et al reported that the significant prognostic impact of EGFR mutations was lost after adjusting for other confounding prognostic factors (4). Several other studies in the literature corroborate this finding (5,6).…”

“…It is to be noted that both EGFR mutation subtypes promoted lung adenocarcinomas with lepidic growth features in transgenic mice (13). Table 1 summarizes ten studies that reported a relationship between EGFR mutation subtypes and prognosis (4,5,11,(14)(15)(16)(17)(18)(19)(20)(21). In focusing on the association between DFS or recurrence and EGFR mutation subtype, Liu et al also reported that patients with Stage I-IIIA lung adenocarcinoma harboring Ex19 had a better DFS rate than those with Ex21 (P=0.056) (14).…”

“…Several studies have reported that EGFR mutations have an impact on prognosis after surgical resection of NSCLCs (3,4). Izar et al demonstrated that the mutation status of EGFR can serve as an independent prognostic marker associated with decreased recurrence and improved progression-free survival and overall survival (OS) in patients with stage I lung adenocarcinoma (3).…”

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

“…The overall response rates were as high as 80% in patients harboring mutations compared with p10% in patients with wildtype EGFR (Huang et al, 2004;Lynch et al, 2004;Mu et al, 2004;Paez et al, 2004;Pao et al, 2004; Sasaki et al, 2006;Kosaka et al, 2007;Yoshida et al, 2007;see Gazdar, 2009).…”